{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:12:40Z","timestamp":1788426760223,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012621","name":"NIHR University College London Hospitals Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010438","name":"The Francis Crick Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jinf.2026.106806","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:05:21Z","timestamp":1783494321000},"page":"106806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence for a relationship between concentrations of nucleos\/tide analogue agents and treatment outcome in chronic hepatitis B infection: A systematic review"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8342-7197","authenticated-orcid":false,"given":"Gloria","family":"Sukali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9974-9684","authenticated-orcid":false,"given":"Motswedi","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7467-7290","authenticated-orcid":false,"given":"Khadija Said","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7928-6555","authenticated-orcid":false,"given":"Patti","family":"Biggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-2367","authenticated-orcid":false,"given":"Marion","family":"Delphin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3200-4087","authenticated-orcid":false,"given":"Joanna M.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongai","family":"Maponga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5753-0107","authenticated-orcid":false,"given":"Katya","family":"Govender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7411-0972","authenticated-orcid":false,"given":"Seth Kwabena","family":"Amponsah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-5855","authenticated-orcid":false,"given":"Catriona","family":"Waitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins","family":"Iwuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-4269","authenticated-orcid":false,"given":"Philippa C.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2026.106806_bib1","series-title":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection","year":"2024"},{"issue":"2","key":"10.1016\/j.jinf.2026.106806_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"European Association for the Study of the Liver","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2026.106806_bib3","unstructured":"US Food and Drug Administration Approves VireadR for Chronic Hepatitis B in Adults. Available at \u3008https:\/\/www.gilead.com\/news\/news-details\/2008\/us-food-and-drug-administration-approves-vireadr-for-chronic-hepatitis-b-in-adults\u3009. [Accessed December 5, 2025]."},{"issue":"8","key":"10.1016\/j.jinf.2026.106806_bib4","article-title":"Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus","volume":"5","author":"Matthews","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jinf.2026.106806_bib5","unstructured":"Global hepatitis report 2024: action for access in low- and middle-income countries:\u00a02024 Available at \u3008https:\/\/www.who.int\/publications\/i\/item\/9789240091672\u3009. [Accessed June 2, 2025]."},{"issue":"1","key":"10.1016\/j.jinf.2026.106806_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12916-018-1229-x","article-title":"Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia","volume":"16","author":"Desalegn","year":"2018","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.jinf.2026.106806_bib7","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/jac\/dkab294","article-title":"Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV\/HBV-coinfected patients: a multicentre prospective cohort study","volume":"76","author":"Dezanet","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2026.106806_bib8","article-title":"Distinct virologic trajectories in chronic hepatitis B identify heterogeneity in response to nucleos(t)ide analogue therapy","volume":"7","author":"Wang","year":"2025","journal-title":"JHEP Rep"},{"issue":"9","key":"10.1016\/j.jinf.2026.106806_bib9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/QAD.0b013e32836011c2","article-title":"Tenofovir-based combination therapy for HIV\/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia","volume":"27","author":"Childs","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.jinf.2026.106806_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jvh.12142","article-title":"Incidence and risk factors for incomplete HBV DNA suppression in HIV\/HBV-co-infected patients initiating tenofovir-based therapy","volume":"21","author":"Hafkin","year":"2014","journal-title":"J Viral Hepat"},{"issue":"9","key":"10.1016\/j.jinf.2026.106806_bib11","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106806_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1471-2334-11-247","article-title":"Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil","volume":"11","author":"Mendes-Correa","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106806_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/426595","article-title":"Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors","volume":"40","author":"Maggiolo","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"101076","key":"10.1016\/j.jinf.2026.106806_bib14","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field","author":"Lumley","year":"2025","journal-title":"Lancet Microbe"},{"issue":"8","key":"10.1016\/j.jinf.2026.106806_bib15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/jvh.13525","article-title":"Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations","volume":"28","author":"Mokaya","year":"2021","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.jinf.2026.106806_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006629","article-title":"A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: a call for urgent action","volume":"12","author":"Mokaya","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jinf.2026.106806_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12688\/wellcomeopenres.15992.1","article-title":"Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms","volume":"5","author":"Mokaya","year":"2020","journal-title":"Wellcome Open Res"},{"issue":"5","key":"10.1016\/j.jinf.2026.106806_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/sextrans-2023-056089","article-title":"Social, clinical and biological barriers to hepatitis B virus suppression with nucleos\/tide analogue therapy: who is at risk and what should we do about it?","volume":"100","author":"Im","year":"2024","journal-title":"Sex Transm Infect"},{"issue":"11","key":"10.1016\/j.jinf.2026.106806_bib19","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/cid\/ciac313","article-title":"Characterizing HIV-preventive, plasma tenofovir concentrations-A pooled participant-level data analysis from human immunodeficiency virus preexposure prophylaxis clinical trials","volume":"75","author":"Garcia-Cremades","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","article-title":"HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention","volume":"66","author":"Donnell","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2026.106806_bib21","unstructured":"TDM monograph Tenofovir (Zoekresultaten voor \u201ctenofovir\u201d). TDM, Toxicology and Pharmacogenetics committee (TTF) of the Dutch Association of Hospital Pharmacists (NVZA) and the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT). Available at \u3008https:\/\/tdm-monografie.org\/?s=tenofovir\u3009. [Accessed February 26, 2025], n.d."},{"issue":"4","key":"10.1016\/j.jinf.2026.106806_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(23)00315-1","article-title":"Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection","volume":"9","author":"Delphin","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jinf.2026.106806_bib23","unstructured":"PROSPERO: Evidence for a relationship between drug levels and treatment outcome in chronic HBV infection: A systematic review. Available at \u3008https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420250599139\u3009. [Accessed November 10, 2025], n.d."},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2016.05.016","article-title":"Entecavir plasma concentrations are inversely related to HBV-DNA decrease in a cohort of treatment-na\u00efve patients with chronic hepatitis B","volume":"48","author":"Boglione","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.jinf.2026.106806_bib25","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2026.106806_bib26","unstructured":"Homepage. European Medicines Agency (EMA). Available at \u3008https:\/\/www.ema.europa.eu\/en\/homepage\u3009. [Accessed January 12, 2026], 2023."},{"issue":"12","key":"10.1016\/j.jinf.2026.106806_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25849","article-title":"Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study","volume":"24","author":"Castillo-Mancilla","year":"2021","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.jinf.2026.106806_bib28","doi-asserted-by":"crossref","first-page":"e01710","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"Anderson","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jinf.2026.106806_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FTD.0000000000000684","article-title":"Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review","volume":"42","author":"Cattaneo","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.jinf.2026.106806_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005842","article-title":"Hepatitis B virus infection as a neglected tropical disease","volume":"11","author":"O\u2019Hara","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.11124\/JBIES-22-00224","article-title":"Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews","volume":"21","author":"Munn","year":"2023","journal-title":"JBI Evid Synth"},{"issue":"2","key":"10.1016\/j.jinf.2026.106806_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hep.27182","article-title":"Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications","volume":"60","author":"Boyd","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/QAD.0000000000003764","article-title":"Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression","volume":"38","author":"Lartey","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2026.106806_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2024.105733","article-title":"Hepatitis B virus (HBV) viremia despite tenofovir disoproxil fumarate-containing antiretroviral therapy in persons with HBV\/HIV coinfection","volume":"175","author":"Ryan","year":"2024","journal-title":"J Clin Virol"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.28461","article-title":"Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus\/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression","volume":"64","author":"Wong","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/cid\/ciae241","article-title":"Cumulative tenofovir exposure among patients with HIV\/Hepatitis B Coinfection with differential viral suppression","volume":"79","author":"Zhang","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/QAI.0000000000003341","article-title":"Relationship between tenofovir diphosphate concentrations in dried blood spots and virological outcomes after initiating tenofovir-lamivudine-dolutegravir as first-line or second-line antiretroviral therapy","volume":"95","author":"van Heerden","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.jinf.2026.106806_bib38","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12981-023-00552-w","article-title":"Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa","volume":"20","author":"Singh","year":"2023","journal-title":"AIDS Res Ther"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0000000000002032","article-title":"A comparison of plasma efavirenz and tenofovir, dried blood spot tenofovir-diphosphate, and self-reported adherence to predict virologic suppression among South African Women","volume":"81","author":"Phillips","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"10.1016\/j.jinf.2026.106806_bib40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/QAD.0000000000003185","article-title":"Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa","volume":"36","author":"Jennings","year":"2022","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.jinf.2026.106806_bib41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/aid.2021.0135","article-title":"Drug resistance, rather than low tenofovir levels in blood or urine, is associated with tenofovir, emtricitabine, and efavirenz failure in resource-limited settings","volume":"38","author":"Jennings","year":"2022","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jinf.2026.106806_bib42","unstructured":"Mohammed KS , Tan CCS, Delphin M, Lumley SF, Matthews PC. Landscape of tenofovir resistance-associated mutations in Hepatitis B Virus 2024. https:\/\/doi.org\/10.6084\/m9.figshare.27255429."},{"issue":"8","key":"10.1016\/j.jinf.2026.106806_bib43","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cmi.2020.03.008","article-title":"How to design a study to evaluate therapeutic drug monitoring in infectious diseases?","volume":"26","author":"M\u00e4rtson","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jinf.2026.106806_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot\u2013based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.jinf.2026.106806_bib45","first-page":"CD007268","article-title":"Therapeutic drug monitoring of antiretrovirals for people with HIV","author":"Kredo","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.jinf.2026.106806_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.8728","article-title":"Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography\/tandem mass spectrometry","volume":"34","author":"Ma","year":"2020","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.jinf.2026.106806_bib47","article-title":"Distribution evaluation of tenofovir in the breast milk of mothers with HBeAg-positive chronic HBV infection after treatment with tenofovir alafenamide and tenofovir disoproxil fumarate by a sensitive UPLC-MS\/MS method","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:16:59Z","timestamp":1788423419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0163445326001313"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106806","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for a relationship between concentrations of nucleos\/tide analogue agents and treatment outcome in chronic hepatitis B infection: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106806"}}